Selected clinical trials in elderly patients using novel agents
| Trial . | N . | Clinical disease features . | Median age, y . | Therapy received/arms of treatment . | Median follow-up, y . | Response . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| BV | 27 | ≥60 years cHL | 78 | BV monotherapy × 16 cycles | ORR 92%, CR 73% | Median PFS 10.5 months | Median OS not reached | |
| BV (BREVITY)40 | 38 | Stage II with B-symptoms or bulky disease, stage III, stage IV unfit for standard chemotherapy | 77 | BV monotherapy × 16 cycles | 3 | ORR 83.9%, CR 25.8% | Median PFS 7.3 months | Median OS 19.5 months |
| BV + bendmaustine (HALO)42 | 59 | Stages III, IV, elderly HL | 70.3 | BV + bendamustine | 1.7 | 2-year PFS 54% | 2-year OS 83% | |
| BV + DTIC41,43 | 19 | Stages I-IV, aged ≥60 years | 69 | BV + dacarbazine | 4.83 | ORR 100%, CR 68% | Median PFS 46.8 months | Median PFS 64 months |
| BV + bendamustine41,43 | 20 | Stages I-IV, aged ≥60 years | 75 | BV + bendamustine | 4.3 | ORR 100%, CR 88% | Median PFS 40.3 months | Median OS 46.9 months |
| BV + nivo (≤16 cycles43 | 21 | Stages I-IV, aged ≥60 years | 72 | BV + nivolumab for up to 16 cycles | 1.6 | ORR 95%, CR 79% | Median PFS not reached | Median OS not reached |
| Sequential BV → AVD in elderly47 | 69 | Stages I, II, III, IV, aged ≥60 years | 69 | BV × 2 → AVD × 6 → BV × 4 | 0.52 | ORR 82%, CR 36% | 2-year PFS 84% | 2-year OS 93% |
| BV + nivolumab (8 cycles) (ACCRU RU051505I)46 | 46 | Stages I, II, III, IV, aged ≥60 years or unsuitable for standard chemotherapy | 71.5 | BV + nivolumab for 8 cycles | 1.8 | ORR 64%, CR 52% | Median PFS 18.3 months | Median OS not reached |
| Trial . | N . | Clinical disease features . | Median age, y . | Therapy received/arms of treatment . | Median follow-up, y . | Response . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| BV | 27 | ≥60 years cHL | 78 | BV monotherapy × 16 cycles | ORR 92%, CR 73% | Median PFS 10.5 months | Median OS not reached | |
| BV (BREVITY)40 | 38 | Stage II with B-symptoms or bulky disease, stage III, stage IV unfit for standard chemotherapy | 77 | BV monotherapy × 16 cycles | 3 | ORR 83.9%, CR 25.8% | Median PFS 7.3 months | Median OS 19.5 months |
| BV + bendmaustine (HALO)42 | 59 | Stages III, IV, elderly HL | 70.3 | BV + bendamustine | 1.7 | 2-year PFS 54% | 2-year OS 83% | |
| BV + DTIC41,43 | 19 | Stages I-IV, aged ≥60 years | 69 | BV + dacarbazine | 4.83 | ORR 100%, CR 68% | Median PFS 46.8 months | Median PFS 64 months |
| BV + bendamustine41,43 | 20 | Stages I-IV, aged ≥60 years | 75 | BV + bendamustine | 4.3 | ORR 100%, CR 88% | Median PFS 40.3 months | Median OS 46.9 months |
| BV + nivo (≤16 cycles43 | 21 | Stages I-IV, aged ≥60 years | 72 | BV + nivolumab for up to 16 cycles | 1.6 | ORR 95%, CR 79% | Median PFS not reached | Median OS not reached |
| Sequential BV → AVD in elderly47 | 69 | Stages I, II, III, IV, aged ≥60 years | 69 | BV × 2 → AVD × 6 → BV × 4 | 0.52 | ORR 82%, CR 36% | 2-year PFS 84% | 2-year OS 93% |
| BV + nivolumab (8 cycles) (ACCRU RU051505I)46 | 46 | Stages I, II, III, IV, aged ≥60 years or unsuitable for standard chemotherapy | 71.5 | BV + nivolumab for 8 cycles | 1.8 | ORR 64%, CR 52% | Median PFS 18.3 months | Median OS not reached |
DTIC, dacarbazine; HL, Hodgkin lymphoma.